Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 8c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.95 -0.83%
Revenue Growth %: +17.5%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +17.5%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.05, $0.08 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $67 million.
GUIDANCE:
Vanda Pharmaceuticals sees Q3 2022 revenue of $240-280 million, versus the consensus of $265.1 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- St. James's Place plc (STJ:LN) (STJPF) PT Raised to GBP20.50 at Deutsche Bank
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
